DUBLIN, August 05, 2021--(BUSINESS WIRE)--The "Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
The Non-steroidal Anti-inflammatory Drugs (NSAIDs) market studied is expected to grow with an estimated CAGR of 5.2%, over the forecast period.
Global market of NSAIDs will have a large impact of Covid-19 on the use and prescription of NSAIDs drugs and the future depends on the results of various trials that are ongoing for understanding the effect of NSAIDs on Covid patients.
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used drugs. These are largely used in the treatment of pain and inflammation. The rising burden of chronic pain and inflammation is driving the demand for NSAIDs. NSAIDs are also used broadly for the treatment of chronic inflammatory disorders such as rheumatoid arthritis and spondyloarthritis.
They are preferred over other drugs because they're inexpensive and they help manage the chronic pain, inflammation, and swelling that are characteristic of rheumatoid arthritis. Globally there is an increase in prevalence and incidence rates of rheumatoid arthritis (RA).
According to an article by Khalid Almutairi (2021) titled "The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review", The global prevalence of RA in 2019 was 460 per 100,000 population, with variations due to geographical location. According to the Centers for Disease Control and Prevention, by 2040, an estimated 78 million (26%) US adults aged 18 years or older are projected to get diagnosed by arthritis. In view of all the mentioned facts, the NSAIDs Market is expected to witness a significant growth over the forecast period.
However, side effect caused by use of NSAIDs is a major barrier in the market growth. The major therapeutic actions of NSAIDs are produced by its ability to inhibit cyclooxygenase enzymes (COX-1 and COX-2). The desired effect of NSAIDs' anti-inflammatory, antipyretic and analgesic response are because of its COX-2 inhibition; while COX-1 inhibition plays a major role in the undesired side effects such as Gastrointestinal and renal toxicities. This is expected to negatively impact the non-steroidal anti-inflammatory drugs market growth.
The NSAIDs market is highly competitive with several players across the globe. In terms of market share, few of the major players currently dominate the market. With the increase in research and development activity, many regional players are expected to contribute in the NSAIDs market over the forecast period.
Some of the major players of the market are Pfizer Inc., GlaxoSmithKline Plc, Johnson & Johnson, Bayer AG, Sanofi S.A., Horizon Therapeutics plc, Sun Pharmaceutical Industries Ltd, Iroko Pharmaceuticals Inc., Reckitt Benckiser Group PLC, Assertio Therapeutics, Inc. and others.
Key Topics Covered:
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Chronic Pain and Inflammation
4.2.2 Preference of NSAIDs over Other Class of Pain Relievers
4.3 Market Restraints
4.3.1 High Cost of Drug Development and Launches
4.3.2 Side Effects of NSAIDs
4.4 Porter's Five Force Analysis
5 MARKET SEGMENTATION
5.1 By Route of Administration
5.2 By Application
5.2.3 Ophthalmic Diseases
5.2.4 Other Applications
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Others Distribution Channels
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 GlaxoSmithKline Plc
6.1.3 Johnson & Johnson
6.1.4 Bayer AG
6.1.5 Sanofi S.A.
6.1.6 Horizon Therapeutics plc
6.1.7 Sun Pharmaceutical Industries Ltd
6.1.8 Iroko Pharmaceuticals Inc.
6.1.9 Reckitt Benckiser Group PLC
6.1.10 Assertio Therapeutics, Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/albjv1
View source version on businesswire.com: https://www.businesswire.com/news/home/20210805005596/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900